Ference Brian A, Majeed Faisal, Penumetcha Raju, Flack John M, Brook Robert D
Division of Translational Research and Clinical Epidemiology, Wayne State University School of Medicine, Detroit, Michigan; Division of Cardiovascular Medicine, Wayne State University School of Medicine, Detroit, Michigan; Department of Internal Medicine, Wayne State University School of Medicine, Detroit, Michigan.
Division of Translational Research and Clinical Epidemiology, Wayne State University School of Medicine, Detroit, Michigan.
J Am Coll Cardiol. 2015 Apr 21;65(15):1552-61. doi: 10.1016/j.jacc.2015.02.020. Epub 2015 Mar 11.
Considerable uncertainty exists as to whether lowering low-density lipoprotein cholesterol (LDL-C) by inhibiting the Niemann-Pick C1-Like 1 (NPC1L1) receptor with ezetimibe, either alone or in combination with a 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) inhibitor (statin), will reduce the risk of coronary heart disease (CHD).
This study evaluated the effect of naturally random allocation to lower LDL-C mediated by polymorphisms in the NPC1L1 gene (target of ezetimibe), the HMGCR gene (target of statins), or both (target of combination therapy) on the risk of CHD.
We constructed NPC1L1 and HMGCR genetic LDL-C scores to naturally randomize participants into 4 groups: reference, lower LDL-C mediated by NPC1L1 polymorphisms, lower LDL-C mediated by HMGCR polymorphisms, or lower LDL-C mediated by polymorphisms in both NPC1L1 and HMGCR. We compared the risk of CHD (fatal or nonfatal myocardial infarction) among each group using a 2 × 2 factorial mendelian randomization study design.
A total of 108,376 persons (10,464 CHD events) from 14 studies were included. There were no significant differences in baseline characteristics among the 4 groups, thus confirming that allocation was random. Compared to the reference group, the NPC1L1 group had 2.4 mg/dl lower LDL-C and 4.8% lower risk of CHD (odds ratio [OR]: 0.952, 95% confidence interval [CI]: 0.920 to 0.985); whereas the HMGCR group had 2.9 mg/dl lower LDL-C and a similar 5.3% lower risk of CHD (OR: 0.947, 95% CI: 0.909 to 0.986). The group with lower LDL-C mediated by both NPC1L1 and HMGCR polymorphisms had 5.8 mg/dl additively lower LDL-C and a 10.8% log-linearly additive lower risk of CHD (OR: 0.892, 95% CI: 0.854 to 0.932).
The effect of lower LDL-C on the risk of CHD mediated by polymorphisms in NPC1L1, HMGCR, or both is approximately the same per unit lower LDL-C and log-linearly proportional to the absolute exposure to lower LDL-C.
关于通过依折麦布抑制尼曼-匹克C1样1(NPC1L1)受体单独或与3-羟基-3-甲基戊二酰辅酶A还原酶(HMGCR)抑制剂(他汀类药物)联合降低低密度脂蛋白胆固醇(LDL-C)是否会降低冠心病(CHD)风险,存在相当大的不确定性。
本研究评估了由NPC1L1基因(依折麦布的作用靶点)、HMGCR基因(他汀类药物的作用靶点)或两者(联合治疗的作用靶点)的多态性介导的自然随机分配降低LDL-C对CHD风险的影响。
我们构建了NPC1L1和HMGCR基因LDL-C评分,将参与者自然随机分为4组:参照组、由NPC1L1多态性介导的LDL-C降低组、由HMGCR多态性介导的LDL-C降低组或由NPC1L1和HMGCR多态性介导的LDL-C降低组。我们使用2×2析因孟德尔随机化研究设计比较了每组中CHD(致命或非致命心肌梗死)的风险。
纳入了来自14项研究的总共108,376人(10,464例CHD事件)。4组之间的基线特征无显著差异,从而证实了分配是随机的。与参照组相比,NPC1L1组的LDL-C降低了2.4mg/dl,CHD风险降低了4.8%(比值比[OR]:0.952,95%置信区间[CI]:0.920至0.985);而HMGCR组的LDL-C降低了2.9mg/dl,CHD风险同样降低了5.3%(OR: